Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q1 2023 · 10-Q
Revenue$114.94K$114.94K−42.3% vs Q1 2022 Net Income-$40.65M-$40.65MN/M vs Q1 2022 EPS Diluted-$1.89-$1.89N/M vs Q1 2022 Operating Income-$43,952,178N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Free Cash Flowderived-$36,961,461N/M Margins · derivedOperating margin-38238.2%−2204.9 pt vs Q1 2022
Net margin-35364.8%+4356.0 pt vs Q1 2022
ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end